|Videos|December 9, 2016

QOL of Multiple Myeloma Patients Receiving Maintenance Therapy

Author(s)Rafat Abonour, MD

This interview examines a study that looked at the health-related quality of life of multiple myeloma patients in a real-world setting who underwent maintenance therapy after autologous stem cell transplant.

In this interview, Rafat Abonour, MD, of the Indiana University Simon Cancer Center, discusses a study that examined the health-related quality of life of multiple myeloma patients who received maintenance therapy in a real-world setting.

Patients in the study (abstract 537) were part of the Connect MM registry. Patients had newly diagnosed disease, and the researchers compared those who received maintenance therapy (a majority with lenalidomide) after autologous stem cell transplant with those who did not.

Dr. Abonour presented results of the trial at the 58th Annual Meeting of the American Society of Hematology (ASH), held December 3–6 in San Diego, California.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Related to this article

“[W]e should strive to increase the [number] of patients…who enjoy long-term disease-free survival and possibly cure,” said Meletios Dimopoulos, MD.

September 25th, 2026

Targeted Agents, Amyloidosis, and Defining a Cure in Plasma Cell Disorders

“[W]e should strive to increase the [number] of patients…who enjoy long-term disease-free survival and possibly cure,” said Meletios Dimopoulos, MD.

Sustained MRD Negativity With DVRd Signals Long-Term Survival in NDMM

September 25th, 2026

Sustained MRD Negativity With DVRd Signals Long-Term Survival in NDMM

Pieter Sonneveld, MD, PhD, explained how sustained MRD negativity with DVRd in the PERSEUS trial may guide long-term outcome counseling in multiple myeloma.

Meletios A. Dimopoulos, MD, explored how anselamimab’s benefit in kappa light chain amyloidosis fits into the evolving role of anti-fibril therapy.

September 24th, 2026

Anselamimab’s Kappa Subgroup Signal Could Reshape Anti-Fibril Therapy in AL Amyloidosis

Meletios A. Dimopoulos, MD, explored how anselamimab’s benefit in kappa light chain amyloidosis fits into the evolving role of anti-fibril therapy.

Meletios A. Dimopoulos, MD, discussed where bispecific antibodies such as teclistamab may fit for patients with relapsed Waldenström macroglobulinemia.

September 23rd, 2026

Defining the Role of Bispecifics in Relapsed Waldenström Macroglobulinemia

Meletios A. Dimopoulos, MD, discussed where bispecific antibodies such as teclistamab may fit for patients with relapsed Waldenström macroglobulinemia.

Rheumatoid arthritis RA in an autoimmune disease faultry activated b cells emitting antibodies which attack the joints causes inflammation front view 3d illustration. with copy space image | Image Credit © vxnaghiyev - stock.adobe.com

September 23rd, 2026

Optimizing Cilta-Cel Sequencing and Community Coordination in Multiple Myeloma

Hematologic specialists discussed where ciltacabtagene autoleucel fits in the treatment paradigm at first relapse and beyond in multiple myeloma.

$An end-of-phase 1 meeting was supported by phase 1b data showing efficacy with LYT-220 among relapsed/refractory myelodysplastic syndrome groups.$

September 22nd, 2026

Novel Monoclonal Antibody Wins FDA Fast Track Designation in High-Risk MDS

An end-of-phase 1 meeting was supported by phase 1b data showing efficacy with LYT-220 among relapsed/refractory myelodysplastic syndrome groups.

The updated NCCN Guidelines for myeloproliferative neoplasms recommend rusfertide as a category 1 option across both low- and high-risk polycythemia vera.

September 22nd, 2026

Rusfertide Earns Category 1 NCCN Recommendation in Polycythemia Vera

The updated NCCN guidelines for myeloproliferative neoplasms recommend rusfertide as a Category 1 option across both low- and high-risk polycythemia vera.

Jasmine Zain, MD, described how pre-existing CHIP mutations should inform pre-infusion risk counseling and treatment selection.

September 19th, 2026

Screening for CHIP Mutations to Guide CAR T-Cell Candidacy in Lymphoma

Jasmine Zain, MD, described how preexisting CHIP mutations should inform preinfusion risk counseling and treatment selection.

Trending on CancerNetwork

The Case for Frontline Zongertinib in HER2-Mutant NSCLC

Durvalumab Plus Enfortumab Vedotin Earns FDA Priority Review in MIBC

Acting on a HER2 Result and Navigating Access to Therapy

FDA Clears TriNav Advance for Expanded Liver Embolization Access

Patient-Centered Treatment Transitions in HR+/HER2− mBC